Samar Elorbany

Samar Elorbany is a Clinical Lecturer and Group Leader specializing in improving therapeutic responses in ovarian and gynaecological cancers. Her research focuses on understanding immune effects of chemotherapy to enhance anti-tumor outcomes and overcome resistance, with the goal of translating findings into clinical trials for better patient survival.

Education: MSc, MD, PhD.

Research Interests:

• Immunotherapy and chemotherapy synergy in ovarian cancer
• Tumour microenvironment dynamics
• Cancer immunology and immune cell behavior
• SOX2 as a biomarker for premalignant lesions

Publication Trends: Recent work emphasizes immunotherapy integration, ex vivo tumor modeling, and biomarker discovery (e.g., SOX2) to address chemotherapy resistance and relapse in high-grade serous ovarian cancer.

Scientific Awards & Funding:

• Cancer Research UK City of London Centre Development fund (2024-2025, £25,000)
• Barts Charity Seed Funding Award (2023-2024, £53,200)
• Wellbeing of Women Clinical Research Training Fellowship (2020-2022, £262,400)

Other Activities: Teaching co-lead for the Cancer Biology module and active member of the British Society of Gynaecological Cancer Society and European Society of Gynaecological Oncology.